Literature DB >> 12087352

Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.

Laurent Becquemont1, Olivier Chazouilleres, Lawrence Serfaty, Jean Marie Poirier, Franck Broly, Patrice Jaillon, Raoul Poupon, Christian Funck-Brentano.   

Abstract

BACKGROUND: Interferon alpha (IFN-alpha) is thought to be responsible for cytochrome P450 (CYP)-dependent drug interactions mediated by a decrease in CYP activities.
OBJECTIVES: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment.
METHODS: Enzymatic activities were determined among 14 patients with chronic active hepatitis C before IFN-alpha (3. 10(6) U, 3 times a week) and ribavirin introduction and after 1 month of treatment. During both study periods, subjects received 80 mg dextromethorphan and 140 mg caffeine (1,3,7-trimethylxanthine [137X]). CYP3A4, CYP2D6, and NAT2 activities were assessed by use of urinary metabolic ratios of 3-methoxymorphinan/dextromethorphan, dextrorphan/dextromethorphan, and 5-acetylamino-6-formylamino-3-methyluracil (AFMU)/1-methylxanthine(1X). The plasma paraxanthine/caffeine ratio was used to measure CYP1A2 activity.
RESULTS: CYP3A4 and CYP2D6 activities tended to increase after 1 month of antiviral therapy, but the change did not reach statistical significance. CYP1A2 and NAT2 activities were not significantly modified after 1 month of antiviral treatment. Pretreatment activities were significantly lower than those previously observed in healthy volunteers for CYP2D6 (mean +/- SD, 148 +/- 139 versus 759 +/- 692; P =.0008) and CYP3A4 (0.18 +/- 0.06 versus 0.52 +/- 0.72; P =.0006). This difference was no longer statistically significant after 1 month of treatment, because CYP2D6 and CYP3A4 activities improved in 7 patients.
CONCLUSION: In patients with chronic hepatitis C, pretreatment CYP3A4 and CYP2D6 activities were significantly lower than those observed in healthy volunteers. These differences disappeared after 1 month of antiviral treatment because of the restoration of these CYP activities in about half of the patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087352     DOI: 10.1067/mcp.2002.124468

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Authors:  Mario Furlanut; Giorgio Soardo; Debora Donnini; Leonardo Sechi; Loretta Franceschi
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

Authors:  Samir K Gupta; Karen Kolz; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

3.  Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.

Authors:  Vanitha Sekar; Sabrina Spinosa-Guzman; Els De Paepe; Tanja Stevens; Frank Tomaka; Martine De Pauw; Richard M W Hoetelmans
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 4.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

5.  Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity.

Authors:  Barbara J Brennan; Zhi-Xin Xu; Joseph F Grippo
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

6.  Salivary caffeine metabolic ratio in alcohol-dependent subjects.

Authors:  Veerapol Kukongviriyapan; Laddawan Senggunprai; Auemduan Prawan; Danu Gaysornsiri; Upa Kukongviriyapan; Jareerat Aiemsa-Ard
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

7.  AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.

Authors:  Sandhya Girish; Steven W Martin; Mark C Peterson; Lei K Zhang; Hong Zhao; Joseph Balthasar; Raymond Evers; Honghui Zhou; Min Zhu; Lewis Klunk; Chao Han; Eva Gil Berglund; Shiew-Mei Huang; Amita Joshi
Journal:  AAPS J       Date:  2011-06-01       Impact factor: 4.009

8.  Immunological response as a source to variability in drug metabolism and transport.

Authors:  Hege Christensen; Monica Hermann
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

Review 9.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

10.  Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes.

Authors:  Dirk Theile; Lelia Wagner; Cindy Bay; Walter Emil Haefeli; Johanna Weiss
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.